Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18866882 | 0.85 | CASP2 (0.53) | ALDH1A1CASP2PSMB5NAAA | |
| SCHEMBL29329063 | 0.84 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1CASP2NAAA | |
| SCHEMBL9943126 | 0.84 | MEN1 (0.63) | MEN1KMT2AALDH1A1CASP2NAAA | |
| SCHEMBL16260385 | 0.84 | MEN1 (0.63) | MEN1KMT2AALDH1A1CASP2NAAA | |
| SCHEMBL25668104 | 0.82 | FAAH (0.50) | MEN1KMT2AALDH1A1CASP2PSMB5 | |
| SCHEMBL25560484 | 0.80 | MEN1 (0.47) | MEN1KMT2AALDH1A1RECQL | |
| SCHEMBL29329056 | 0.79 | ECE1 (0.39) | MEN1KMT2AALDH1A1CASP2RECQL | |
| SCHEMBL16248535 | 0.79 | ALDH1A1 (0.53) | ALDH1A1CASP2 | |
| SCHEMBL24398829 | 0.78 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1 | |
| SCHEMBL25443782 | 0.78 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11708413-B2 | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-10858349-B2 | Compositions and methods for the treatment of cancer | CELLIX BIO PRIVATE LIMITED (IN) | 2020-12-08 | — | — | US | disclosed |
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2019-09-26 | — | — | US | disclosed |
| US-20190144546-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2019-05-16 | — | — | US | disclosed |
| WO-2017132617-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017132615-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | MEN1 2358/4885KMT2A 3176/4885ALDH1A1 1241/4885 |
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | SI, HBG2, HBG1 | MEN1 999/4885KMT2A 4424/4885ALDH1A1 2768/4885 |
| US-11708413-B2 | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates | CD74, CD63, CD99 | MEN1 2336/4885KMT2A 2960/4885ALDH1A1 1164/4885 |
| US-10858349-B2 | Compositions and methods for the treatment of cancer | SI, HBG2, HBG1 | MEN1 999/4885KMT2A 4424/4885ALDH1A1 2768/4885 |
| US-20190144546-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD99, CD63 | MEN1 4062/4885KMT2A 156/4885ALDH1A1 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.